Q3 2025 update

22 October 2025



IPSEN

Forward-looking statements

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new medicine can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. Ipsen must deal with or may have to deal with competition from generic medicines that may result in market-share losses, which could affect its level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law.

All medicine names listed in this document are either licensed to Ipsen or are registered trademarks of Ipsen or its partners.

The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.

In those countries in which public or private-health cover is provided, Ipsen is dependent on prices set for medicines, pricing and reimbursement-regime reforms and is vulnerable to the potential withdrawal of certain medicines from the list of reimbursable medicines by governments, and the relevant regulatory authorities in its locations.

Ipsen operates in certain geographical regions whose governmental finances, local currencies or inflation rates could erode the local competitiveness of Ipsen's medicines relative to competitors operating in local currency, and/or could be detrimental to Ipsen's margins in those regions where Ipsen's sales are billed in local currencies.

In a number of countries, Ipsen markets its medicines via distributors or agents; some of these partners' financial strengths could be impacted by changing economic or market conditions, potentially subjecting Ipsen to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by changing economic or market conditions, and where Ipsen sells its medicines directly to hospitals, Ipsen could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full.

Ipsen also faces various risks and uncertainties inherent to its activities identified under the caption 'Risk Factors' in the Company's Universal Registration Document as well as risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the Unites States.

All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.

Speakers

Presentation

David Loew
Chief Executive Officer

Joining for Q&A

Aymeric Le Chatelier
Chief Financial Officer

Christelle Huguet
Head of R&D

Today's highlights

Financial Performance

Sales Growth at CER[1]

Q3: +13.7%

YTD: +12.1%
Somatuline®: +11.7%
Rest of Portfolio: +12.3%

Upgraded 2025 Guidance[2]

Total sales growth:

~10.0% (prior >7.0%)

Core operating margin:
~35.0% of total sales (prior >32.0%)

Q3 Pipeline Progression

IPN10200: LANTIC Phase II in aesthetics delivering a first-in-class, long-acting clinical profile

Bylvay®: Japan approval for PFIC[3]

Cabometyx®: EU approval in NETs[4]

ImCheck acquisition[5]

Expanding the pipeline in Oncology:

Phase IIb/III ready asset in AML[6]

[1] At constant exchange rates; [2] Based on the average level of exchange rates in September 2025, an adverse impact on total sales of around 3% from currencies is expected;
[3] **PFIC:** Progressive Familial Intrahepatic Cholestasis; [4] **NETs:** Neuroendocrine Tumors; [5] ImCheck Therapeutics transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions;
[6] **AML:** Acute Myeloid Leukemia

Expanding our pipeline in Oncology

Proposed acquisition of ImCheck Therapeutics

Lead clinical-stage program ICT01: first-in-class monoclonal antibody targeting BTN3A

Phase I/II EVICTION[1] trial ongoing: evaluating ICT01 in combination with venetoclax and azacitidine in 1L unfit AML[2]

1L unfit AML patients

- Lead indication with high unmet need
- Adult 5-year survival in U.S. is 30%
- Oral presentation of interim data at ASCO 2025[3]
- Data showed unprecedented high response to treatment[3]

Phase IIb/III planned to start in 2026

[1] ClinicalTrials.gov: IDNCT04243499; **1L**: first line; **AML**: Acute Myeloid Leukemia; [2] First-line unfit AML including high risk patients who are ineligible for intensive chemotherapy
[3] **ASCO 2025:** American Society of Clinical Oncology Annual Meeting 2025 available at: https://www.lmChecktherapeutics.com/fileadmin/Posters_Prez/ASCO2025-ICT01-AzaVen.pdf

Q3 & YTD sales performance

	Q3 2025		YTD 2025	
	€m	% change	€m	% change
Oncology	624	7.0%	1,912	6.6%
Rare Disease	102	109.1%	255	101.0%
Neuroscience	189	9.1%	567	9.5%
Total Sales	**915**	**13.7%**	**2,735**	**12.1%**
Total sales growth excl. Somatuline®		16.7%		12.3%

Growth at constant exchange rates

Oncology portfolio

Q3 YTD 2025 sales growth of 6.6%



Somatuline® autogel® lanreotide

€868m

+11.7%

Solid growth in the U.S. & Europe, continued generic lanreotide shortages

Strong performance in Rest of World

CABOMETYX® (cabozantinib) tablets

€452m

+2.9%

Solid performance in Europe reflecting increasing market share in RCC 1L

Solid Q3 sales in Rest of World despite challenging first half due to competition

Decapeptyl® triptorelin

€406m

+2.2%

Volume growth in Europe and Rest of World, despite continued competition, offset by pricing pressure in certain countries

onivyde® (irinotecan liposome injection)

€151m

+4.8%

Moderate sales growth in the U.S. in 1L & 2L

Solid performance from ex-U.S. partner

RCC: Renal Cell Carcinoma; **1L:** First Line; **2L:** Second Line
Growth at constant exchange rates

Rare Disease portfolio

Q3 YTD 2025 sales growth of 101.0%



Bylvay (odevixibat)
200 | 400 | 600 | 1200 mcg capsules

€135m
+46.4%

Strong volume growth in the U.S. driven by PFIC and ALGS indications

Increased ex-U.S. contribution in PFIC from new patient initiations, dosing & geographical expansion

IQIRVO elafibranor

€107m
-

Accelerated sales growth in the U.S. and in Europe driven by increasing uptake from new patients, switch & market expansion

PFIC: Progressive Familial Intrahepatic Cholestasis; **ALGS:** Alagille Syndrome
Growth at constant exchange rates



Neuroscience portfolio

Q3 YTD 2025 sales growth of 9.5%

Dysport® ABOBOTULINUM TOXIN A

Aesthetics

€337m

+12.3%

Continued strong sales growth in the U.S. and in Rest of World in Ipsen's & partner's territories

Q3 performance in Europe impacted by phasing of shipments to partner

Dysport® ABOBOTULINUM TOXIN A

Therapeutics

€221m

+5.2%

Solid growth in the U.S. and Europe

Rest of World strong growth in Q3; first half impacted by phasing of orders in Brazil

Growth at constant exchange rates

Growing pipeline across three therapeutic areas

Oncology
Rare Disease
Neuroscience

Information shown as of September 2025



R²: Lenalidomide + rituximab; **2L:** Second line; **FL:** Follicular lymphoma; **1L:** First line; **pLGG:** Pediatric low-grade gliomas; **ERKi:** ERK inhibitor of the MAPK pathway; **RAFi:** RAF inhibitor of the MAPK pathway; **BA:** Biliary Atresia; **PBC:** Primary biliary cholangitis; **PSC:** Primary sclerosing cholangitis; **FOP:** Fibrodysplasia ossificans progressiva; **GL:** Glabellar lines; **FHL:** Forehead lines; **LCL:** Lateral canthal lines; **AUL:** Adult upper limb spasticity; **Ax:** Aesthetics; **Tx:** Therapeutics

[1] Executed by Day One Biopharmaceuticals; [2] Registrational trial

IPN10200: First-in-class profile

A differentiated long-acting recombinant molecule

Phase II LANTIC Stage 1 data[1] in aesthetics (Glabellar lines):

- Rapid onset of action
- Statistically significant response to treatment at Week 4[2]
- Substantial majority of patients experiencing clinically significant longer duration of effect at Week 24; continued greater response at Week 36[3]
- Superior patient satisfaction scores

LANTIC Stage 2 & 3 ongoing in FHL and LCL

Phase II development ongoing for Tx indications

Full data to be presented H1 2026
Phase III activities initiated in Glabellar lines

[1] n=184 in Stage 1 of the ongoing Phase I/II LANTIC study evaluating IPN10200 in GL;
[2] IPN10200 has shown a statistically significant improvement in response compared to placebo, as measured by the primary endpoint of composite response of 2-grade improvement on both Investigator and Subject assessment of line severity at Week 4
[3] Substantial majority of patients experienced a clinically significant response as defined as a score of "none" or "mild" as measured by Investigator assessment of line severity at Weeks 24 and 36 compared with placebo and Dysport®
FHL: Forehead lines; **LCL:** Lateral canthal lines; **GL:** Glabellar lines

Major upcoming milestones



Information shown as of September 2025

FOP: Fibrodysplasia ossificans progressiva; **R/R:** Relapsed/refractory; **pLGG:** Pediatric low-grade gliomas; **BA:** Biliary atresia; **PBC:** Primary biliary cholangitis; **CM:** Chronic migraine ; **EM:** Episodic migraine

[1] Registrational trial; [2] Executed by Day One Biopharmaceuticals

Key takeaways

Executing on 2025 priorities

Delivering Strong Financials

- Solid double-digit sales growth momentum
- Further upgraded guidance

Expanding Pipeline

- Ipsen to acquire ImCheck Therapeutics[1]
- IPN10200, a differentiated first-in-class long-acting recombinant molecule
- Key further catalysts to come over the next 18 months

[1] ImCheck Therapeutics transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions

Questions

Appendix

Currency impact YTD 2025 sales

Adverse impact of -2.6pts

YTD 2025 sales by currency



Average rate changes (YTD 2025 vs. YTD 2024)



Oncology

Key ongoing clinical-trial highlights

Trial	Indication	Patients	Design	Primary Endpoint(s)	Status
Tazverik SYMPHONY-1 Phase III NCT04224493	R/R FL	612	Tazverik + R^2 or placebo + R^2	PFS	Recruiting[1]
tovorafenib FIREFLY-2 Phase III NCT05566795	1L pLGG	400	tovorafenib or chemotherapeutic	ORR	Recruiting[1,2]
IPN01194 Phase I/IIa NCT06305247	Solid tumors (advanced)	220	IPN01194	Safety and efficacy	Recruiting[1]
IPN01195 Phase I/IIa NCT06833008	Solid tumors (advanced)	85	IPN01195	Safety and efficacy	Recruiting[1]

R/R: Relapsed/refractory; **FL**: Follicular lymphoma; **R^2**: Lenalidomide + rituximab; **PFS**: Progression-free survival; **1L**: First line; **pLGG**: Pediatric low-grade glioma; **ORR**: Overall response rate

[1] Recruitment status as per ct.gov, September 2025; [2]Executed by Day One Biopharmaceuticals

Rare Disease

Key ongoing clinical-trial highlights

Trial	Indication	Patients	Design	Primary Endpoint(s)	Status
Bylvay BOLD Phase III NCT04336722	BA	254	Placebo or Bylvay	Time from randomization to first occurrence of liver transplant, or death	Active, not recruiting[1]
Iqirvo ELSPIRE[2] Phase III NCT06383403	2L PBC	69	Placebo or Iqirvo	Percentage of participants with normalisation of ALP levels	Active, not recruiting[1]
Iqirvo ELMWOOD Phase II NCT05627362	PSC	68	Placebo or Iqirvo	Safety and tolerability	Active, not recruiting[1]
fidrisertib FALKON[3] Phase II NCT05039515	FOP (chronic)	98	Placebo or two dosing of fidrisertib	Annualized change in HO volume as assessed by low-dose WBCT (excluding the head) in treated participants compared with placebo	Active, not recruiting[1]

BA: Biliary atresia; **2L:** Second line; **PBC:** Primary biliary cholangitis; **ALP:** Alkaline phosphatase; **PSC:** Primary sclerosing cholangitis; **FOP:** Fibrodysplasia ossificans progressive; **HO:** Heterotopic ossification; **WBCT:** Whole-Body Computed Tomography

[1] Recruitment status as per ct.gov, September 2025; [2] Based on ALP >1.00 × ULN and <1.67 × ULN; [3]Registration trial

Neuroscience – IPN10200

Key ongoing clinical-trial highlights

Trial	Indication	Patients	Design	Primary Endpoint(s)	Status
IPN10200 LANTIC Phase II NCT04821089	Stage 1 : Moderate to severe GL	727	Dose escalation & dose-finding versus Dysport or placebo	Response - composite response of 2-grade improvement on SSA at maximum contraction at w4	Active, not recruiting[1]
	Stage 2 : Moderate to severe GL + FHL, FHL or LCL		Dose-finding versus placebo		Recruiting[1]
	Stage 3 : Moderate to severe in GL, FHL and LCL		Placebo-controlled safety evaluation		Recruiting[1]
IPN10200 LANTIMA Phase II NCT04752774	Adult patients with upper-limb spasticity	240	Dose escalation & dose-finding versus Dysport or placebo	Efficacy and safety	Recruiting[1]
IPN10200 MERANTI Phase II NCT06625060	Adults with chronic or episodic migraine	641	Dose escalation & dose-finding versus placebo	Efficacy and safety	Recruiting[1]
IPN10200 CATALPA Phase II NCT06937931	Adults with cervical dystonia	132	Dose escalation & dose-finding versus placebo	Efficacy and safety	Recruiting[1]

GL: Glabellar lines; **FHL:** Forehead lines; **LCL:** Lateral canthal lines [1] Recruitment status as per ct.gov, September 2025

Neuroscience – Dysport

Key ongoing clinical-trial highlights

Trial	Indication	Patients	Design	Primary Endpoint(s)	Status
Dysport C-BEOND Phase III NCT06047444	Chronic migraine	720	Two dosing regimes of Dysport or placebo	Change from baseline in monthly migraine days (MMD)	Recruiting[1,2]
Dysport E-BEOND Phase III NCT06047457	Episodic migraine	714	Two dosing regimes of Dysport or placebo	Change from baseline in monthly migraine days (MMD)	Recruiting[1,2]

[1] Pre-defined step of trial design; [2] Recruitment status as per ct.gov, September 2025

Investor Relations

Henry Wheeler

Vice President Investor Relations

+33 7 64 47 11 49

henry.wheeler@ipsen.com

Khalid Deojee

Senior Manager Investor Relations

+33 6 66 01 95 26

khalid.deojee@ipsen.com

Thank You

IPSEN

Learn more about us